Ipamorelin's One Trial Missed Its Endpoint

How much human evidence is there in total?

Two records. Searched in August 2026 the molecule returns 54 indexed papers, 28 carrying the Humans subject heading, and exactly 2 under the clinical-trial publication type — both of which also carry the stricter randomized-controlled-trial type ^[3].

Both were read rather than counted. One is a dose-escalation pharmacokinetic and pharmacodynamic study in healthy male volunteers, eight subjects at each of five fifteen-minute infusion rates, measuring concentrations of the peptide and of growth hormone and modeling the relation between them ^[2]. That is a study of what the compound does to a hormone, not of what it does to a person.

The other is the trial this page is about. The publication-type filter was proved live in the same session against a control term returning 8,904 records under the clinical-trial type and 6,113 under the randomized type, the invalid tag that once produced a false zero on this site returned 0 for that same control term, and a deliberately invalid record identifier errored in the same run ^[3].

What did the randomized trial actually test?

It tested postoperative ileus — the temporary shutdown of bowel motility that follows abdominal surgery — in adults undergoing small and large bowel resection by open or laparoscopic technique. The rationale was mechanistic and reasonable: ipamorelin acts at the growth hormone secretagogue receptor, the receptor ghrelin binds, and ghrelin-receptor stimulation has promotility effects in the gut ^[1].

The design was a multicenter, double-blind, placebo-controlled phase 2 study, registered as NCT00672074. Patients received intravenous infusions of ipamorelin at 0.03 mg per kilogram or placebo twice daily from the first postoperative day until day seven or hospital discharge. One hundred seventeen patients were enrolled and 114 made up the safety and modified intention-to-treat populations. The key efficacy endpoint was the time from the first dose to tolerance of a standardized solid meal ^[1].

That is a well-formed trial asking a well-formed question, and it deserves to be described as one. The reason it appears in an index of gray-market peptides is that it is the only controlled outcome evidence this compound has, and it is almost never the evidence a reader is shown.

What was the result?

Median time to first tolerated meal was 25.3 hours in the ipamorelin group and 32.6 hours in the placebo group, at p equal to 0.15 ^[1]. The direction favored the drug. The difference did not reach statistical significance.

The authors state the conclusion themselves and state it plainly: there were no significant differences between ipamorelin and placebo in the key or the secondary efficacy analyses ^[1]. Safety was unremarkable, with treatment-emergent adverse events in 87.5 percent of the ipamorelin group and 94.8 percent of the placebo group, and the authors describe the regimen as well tolerated ^[1]. They also name their own limitations, calling the study small and noting that it enrolled patients with a broad range of underlying conditions ^[1].

A seven-hour difference in median time to a meal, in the direction of benefit, at p equal to 0.15, in 114 patients, is exactly the kind of result that gets rewritten by other people into a claim. It is not a positive trial. It is not a demonstration that the compound does nothing either. It is an underpowered proof-of-concept study that did not separate from placebo, which is a specific and useful thing to know and a poor foundation for anything.

Why does this trial not support what the compound is sold for?

It was run in a different population, at a different route, for a different indication. The subjects were hospital inpatients recovering from bowel surgery, receiving an intravenous infusion twice daily for up to a week, and the endpoint was gastrointestinal recovery. The compound is marketed to healthy adults, self-injected subcutaneously, for body composition, recovery, and aging.

Nothing in the trial speaks to any of that, and the pharmacokinetic study speaks to it only in the narrow sense that the compound reaches the bloodstream and releases growth hormone in a dose-related way ^[2]. Read together, the two records say that ipamorelin does the hormonal thing it is designed to do, and that the single time anyone measured whether it changed a clinical outcome, it did not.

The pairing with CJC-1295 that dominates the market is worth naming for the same reason: it was invented by sellers rather than by any trial, and neither half of it has an outcome study behind it. CJC-1295's nomination was withdrawn in September 2024, and sermorelin shows what a lawful position in the GH secretagogues class looks like — though its own trial record stopped in 2005.

Where does that leave ipamorelin in the United States?

On no list. Its nomination to the section 503A bulks list was withdrawn in September 2024 and it was removed from Category 2 without being added to Category 1, so there is no lawful compounding route; it was not among the peptides reviewed at the July 2026 advisory committee meeting. The monograph records that ledger with the date each entry was verified, and the nomination tracker shows how often a withdrawal is reported as a clearance.

Material sold under the name is research-use-only chemical supply, produced and sold outside pharmacy licensure and prescriber oversight, and its identity, purity, and sterility are whatever the vendor asserts them to be. That is a separate problem from the evidence, and it compounds it: the one trial that exists administered a manufactured product at a stated dose under a protocol, and the trial's result — which was neutral — does not attach to the contents of an unlabeled vial. The research-only page sets out why removal from a prohibition list is not permission.

Elsewhere in this index